All In MedTech

Device Trial Radar · NCT03918564

ReShape Vest™ for the Treatment of Obesity (Europe)

An Investigative, Prospective, Non-randomized, Multi-center Study to Assess the Safety and Effectiveness of a Novel Gastric Restrictive Device, Call the ReShape Vest™, in People Who Are Obese.

Last checked: Nov 20, 2026Latest source record: Feb 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

65

Planned (sponsor's estimate)

Start

Mar 25, 2019

Primary completion

Dec 2020

Study completion Dec 2021

Sponsor

Lead sponsor
ReShape LifesciencesNot on our public-company list
Sponsor type
Industry
First posted
Apr 17, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 22 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the safety and effectiveness of the LGV in treating obese subjects with a BMI of 35 kg/m2 to 55 kg/m2 who have failed one or more conservative weight-reduction alternative(s), such as supervised diet, exercise, and behavior modification program(s).

Conditions

  • Obesity
  • Weight Loss

Interventions

  • Laparoscopic Gastric Vest (LGV)Device

    The Laparoscopic Gastric Vest (LGV), branded the ReShape Vest™, is a long-term, silastic, implantable system that is placed around the stomach to encompass the gastroesophageal junction to the Incisura Angularis. The main materials used to make the LGV is Implant Grade Silicone (95%) and Barium Sulfate (5%). The LGV is indicated for weight reduction for obese people with a Body Mass Index (BMI) between ≥35 kg/m2 and ≤55 kg/m2. It is indicated for use in adult patients (≥22 to ≤65 years) who have failed one or more conservative weight reduction alternative(s), such as supervised diet, exercise, and behavior modification program(s).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. %Excess Weight LossTime frame: 12 Months

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital universitario de Bellvitge

    Barcelona, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.